Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $135,383.20 in Stock

SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) insider Anthony J. Recupero sold 5,459 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $24.80, for a total transaction of $135,383.20. Following the sale, the insider now directly owns 222,356 shares of the company’s stock, valued at approximately $5,514,428.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

SI-BONE Stock Performance

SIBN opened at $26.22 on Friday. The firm has a 50-day simple moving average of $21.33 and a two-hundred day simple moving average of $17.30. SI-BONE, Inc. has a 52 week low of $11.14 and a 52 week high of $27.24. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.72 and a quick ratio of 6.65.

SI-BONE (NASDAQ:SIBN – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.10. SI-BONE had a negative net margin of 47.11% and a negative return on equity of 54.17%. The business had revenue of $31.95 million during the quarter, compared to the consensus estimate of $31.80 million. Equities analysts predict that SI-BONE, Inc. will post -1.44 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SIBN. Paradigm Capital Management Inc. NY boosted its holdings in shares of SI-BONE by 1,003.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 695,071 shares of the company’s stock valued at $9,453,000 after purchasing an additional 632,071 shares during the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in shares of SI-BONE by 154.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 900,969 shares of the company’s stock valued at $17,722,000 after acquiring an additional 547,141 shares during the last quarter. First Light Asset Management LLC lifted its holdings in shares of SI-BONE by 50.6% in the 1st quarter. First Light Asset Management LLC now owns 1,084,634 shares of the company’s stock valued at $24,513,000 after acquiring an additional 364,391 shares during the last quarter. Pier Capital LLC bought a new position in shares of SI-BONE in the 4th quarter valued at about $4,849,000. Finally, Granahan Investment Management LLC lifted its holdings in shares of SI-BONE by 29.7% in the 4th quarter. Granahan Investment Management LLC now owns 1,162,484 shares of the company’s stock valued at $15,810,000 after acquiring an additional 266,009 shares during the last quarter. Institutional investors own 98.03% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of SI-BONE from $18.00 to $22.00 and gave the company an “overweight” rating in a research report on Tuesday, February 28th. Canaccord Genuity Group lifted their target price on shares of SI-BONE from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 28th. Truist Financial lifted their target price on shares of SI-BONE from $26.00 to $28.00 in a research note on Tuesday, May 2nd. Cantor Fitzgerald lifted their target price on shares of SI-BONE from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday, February 28th. Finally, Needham & Company LLC lifted their target price on shares of SI-BONE from $24.00 to $27.00 in a research note on Tuesday, May 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.29.

About SI-BONE

(Get Rating)

SI-BONE, Inc engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.